Immunotherapy Advances in Small Cell Lung Cancer
This article reviewed the clinical studies of immune checkpoint inhibitors (ICIs) in the first-line, maintenance and second or more line treatment of SCLC. Besides, predictive biomarkers were discussed to select suitable patients for immunotherapy effectively. DOI: 10.3779/j.issn.1009-3419.2020.105.02
Source: Chinese Journal of Lung Cancer - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | China Health | Clinical Trials | Immunotherapy | Lung Cancer | Small Cell Lung Cancer | Study